About CLARUS BIOLOGICS, INC
Clarus Biologics is a biotechnology company focused on developing next-generation adjuvants, particularly Viral Like Particles (VLP), to improve the safety, efficacy, and availability of vaccines and immunotherapies. Their product, CBI-3A, has demonstrated strong pre-clinical results across multiple species.
Development of novel Viral Like Particles (VLP) adjuvantsElicitation of immune responses from all three elements of the adaptive immune systemStimulation of innate immune responsesDemonstration of stronger immune responses compared to antigen or vaccine alone and other simple adjuvantsGeneration of antibody, T-cell, and mucosal immune responsesMucosal immune responses with intramuscular administrationAntigen sparing capabilities to reduce costs and mitigate supply constraints
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to CLARUS BIOLOGICS, INC right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.